Axogen To Acquire BioCircuit Technologies

September 10, 2026 — 06:16 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Axogen (AXGN) has entered into a definitive agreement to acquire BioCircuit Technologies, a privately held medical device company and developer of NerveTape, the first FDA-approved device for sutureless nerve repair. Axogen will acquire BioCircuit for total consideration of $200 million in cash at closing. At closing, $1.0 million of the estimated merger consideration will be withheld pending determination of the post-closing purchase price adjustment.

Axogen expects the acquisition to be accretive to revenue growth, adjusted EBITDA margin and adjusted earnings per share in the first year following close, while maintaining positive free cash flow.

In pre-market trading on NasdaqCM, Axogen shares are down 5.01 percent to $44.90.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Axogen To Acquire BioCircuit Technologies

Tags

Latest Articles